No Data
No Data
No Data
No Data
No Data
Atara Biotherapeutics, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Atara Biotherapeutics, Inc. (NASDAQ:ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and
BusinesswireApr 6 04:01
Atara Biotherapeutics Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 04/01/2024 221.5% Stifel $4.8 → $2.3 Maintains Hold 11/10/2023 -30.11% Goldman Sachs $3 → $0.5 Maintains S
BenzingaApr 1 22:53
Stifel Adjusts Atara Biotherapeutics Price Target to $2.30 From $4.80, Maintains Hold Rating
Stifel Adjusts Atara Biotherapeutics Price Target to $2.30 From $4.80, Maintains Hold Rating.
MT NewswiresApr 1 21:27
Analysts Offer Insights on Healthcare Companies: Atara Biotherapeutics (ATRA) and Embecta Corporation (EMBC)
TipRanksApr 1 19:30
Analysts Offer Insights on Healthcare Companies: Affimed (AFMD) and Atara Biotherapeutics (ATRA)
TipRanksApr 1 10:20
Atara Biotherapeutics Board Member Decides Not to Seek Re-Election
Atara Biotherapeutics (ATRA) just unveiled an announcement.
TipRanksMar 30 04:43
No Data
No Data